Skip to main content
. Author manuscript; available in PMC: 2022 Jun 2.
Published in final edited form as: Pediatr Blood Cancer. 2020 Nov 2;68(2):e28787. doi: 10.1002/pbc.28787

FIGURE 3.

FIGURE 3

Pharmacodynamic markers. (A) Sustained modulation of S6K phosphorylation and (B) c-MYC expression with Everolimus. (C) Progressive modulation of 4E-BP1 phosphorylation with Everolimus. Data was normalized to highest value within each patient group using two-way repeated measures ANOVA (n=8)